Forecast & Rating2 analysts currently cover Theriva Biologics, of which 2 give a positive rating. The average price target is $2.50, about 909.7% upside from the current price of $0.25. Coverage is limited, so the data is for reference only. Data as of Aug 12, 2026; this does not constitute investment advice.
Aug 12, 2026Price forecast
$2.50909.69%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateSep 7, 2026
Forecast met0.0%
Stock price$0.25
Avg. target$7.0
High target$7
Low target$7
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.